CXCL10 is a crucial chemoattractant for efficient intranasal delivery of mesenchymal stem cells to the neonatal hypoxic-ischemic brain

Hermans, Eva C.; Donega, Vanessa; Heijnen, Cobi J.; de Theije, Caroline G.M.; Nijboer, Cora H.

CXCL10 is a crucial chemoattractant for efficient intranasal delivery of mesenchymal stem cells to the neonatal hypoxic-ischemic brain

Files

s13287-024-03747-8.pdf (8.76 MB)

Date

2024

Authors

Hermans, Eva C.

Donega, Vanessa

Heijnen, Cobi J.

de Theije, Caroline G.M.

Nijboer, Cora H.

Publisher

Springer Nature

Abstract

Hypoxic-Ischemic Encephalopathy (HIE) is a leading cause of mortality and morbidity in newborns. Recent research has shown promise in using intranasal mesenchymal stem cell (MSC) therapy if administered within 10 days after Hypoxia-Ischemia (HI) in neonatal mice. MSCs migrate from the nasal cavity to the cerebral lesion in response to chemotactic cues. Which exact chemokines are crucial for MSC guidance to the HI lesion is currently not fully understood. This study investigates the role of CXCL10 in MSC migration towards the HI-injured brain.

Type

Journal article

Citation

Hermans, E. C., Donega, V., Heijnen, C. J., de Theije, C. G. M., & Nijboer, C. H. (2024). CXCL10 is a crucial chemoattractant for efficient intranasal delivery of mesenchymal stem cells to the neonatal hypoxic-ischemic brain. Stem Cell Research & Therapy, 15(1), 134. https://doi.org/10.1186/s13287-024-03747-8

Published Version

https://doi.org/10.1186/s13287-024-03747-8

Rights

Except where otherwise noted, this work is licensed under a Creative Commons Attribution (CC BY) license. Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.